307 related articles for article (PubMed ID: 26893445)
21. Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Ajmal M; Friedman J; Sipra QUAR; Lassar T
Cardiovasc Ther; 2021; 2021():8886210. PubMed ID: 33505518
[TBL] [Abstract][Full Text] [Related]
22. Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism.
Bauersachs R; Koitabashi N
Int Heart J; 2017 Feb; 58(1):6-15. PubMed ID: 28123163
[TBL] [Abstract][Full Text] [Related]
23. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
25. How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing.
Liu XQ; Yin YW; Wang CY; Li ZR; Zhu X; Jiao Z
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1153-1163. PubMed ID: 34058934
[TBL] [Abstract][Full Text] [Related]
26. [Rivaroxaban in the prevention and treatment of thromboembolic disorders].
Helbing T; Bode C; Moser M
Hamostaseologie; 2012; 32(3):195-202. PubMed ID: 22777255
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
[TBL] [Abstract][Full Text] [Related]
29. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF).
Lip GY; Hammerstingl C; Marin F; Cappato R; Meng IL; Kirsch B; Morandi E; van Eickels M; Cohen A
Am Heart J; 2015 Apr; 169(4):464-71.e2. PubMed ID: 25819852
[TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Mega JL; Braunwald E; Mohanavelu S; Burton P; Poulter R; Misselwitz F; Hricak V; Barnathan ES; Bordes P; Witkowski A; Markov V; Oppenheimer L; Gibson CM;
Lancet; 2009 Jul; 374(9683):29-38. PubMed ID: 19539361
[TBL] [Abstract][Full Text] [Related]
32. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
34. [CHANGE OF ANTICOAGULANT EFFECT OF RIVAROXABAN DURING A DAY].
Gel'tser IV; Smirnova OA; Matvienko OY; Golovina OG; Papayan LP
Vestn Khir Im I I Grek; 2015; 174(4):77-9. PubMed ID: 26601525
[TBL] [Abstract][Full Text] [Related]
35. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
36. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Eriksson BI; Quinlan DJ; Eikelboom JW
Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
[TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Kwong LM
Orthopedics; 2012 Jun; 35(6):e932-8;discussion e939. PubMed ID: 22691670
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
39. Model-Based Assessment Using Conventional Bioequivalence Limits to Ensure Safety and Efficacy of Rivaroxaban in Patients Undergoing Hip or Knee Replacement.
González-Sales M; Fang L; Kim MJ; Zhao L
J Clin Pharmacol; 2017 Dec; 57(12):1591-1599. PubMed ID: 28926095
[TBL] [Abstract][Full Text] [Related]
40. Rivaroxaban: An Evaluation of its Cardiovascular Benefit-Risk Profile Across Indications Based on Numbers Needed to Treat or Harm, and on Clinically Meaningful Endpoint Comparisons.
Ageno W
Drugs R D; 2015 Dec; 15(4):295-306. PubMed ID: 26416655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
